Fast Facts: Non-Small-Cell Lung Cancer PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Fast Facts: Non-Small-Cell Lung Cancer PDF full book. Access full book title Fast Facts: Non-Small-Cell Lung Cancer by Mary O'Brien. Download full books in PDF and EPUB format.
Author: Mary O'Brien Publisher: Karger Medical and Scientific Publishers ISBN: 3318070106 Category : Medical Languages : en Pages : 148
Book Description
Despite an overall decrease in tobacco use, lung cancer (80–85% of which is non-small-cell lung cancer [NSCLC]) is still the leading cause of cancer death in both men and women worldwide. Annual low-dose CT screening of high-risk individuals has the potential to detect early-stage tumors, which can usually be successfully treated with a combination of surgery, radiotherapy and chemotherapy and, in some cases, targeted therapy. However, most patients with NSCLC still present with advanced or metastatic disease. For these patients, initial therapy is guided by the tumor’s molecular characteristics and patient’s performance status. Targeted therapies have significantly improved clinical outcomes and, for some patients with no targetable genetic alterations, immunotherapy has demonstrated significant overall survival benefit. This insightful guide is designed to bring you up to speed with the latest developments and is important reading for all health professionals and medical trainees working in this fast-moving field. Table of Contents: • Prevention and screening • Diagnosis and staging • Surgery • Radiotherapy • Systemic therapy in non-metastatic NSCLC • Systemic therapy in advanced-stage/metastatic disease without a molecular driver • Personalized treatment in advanced NSCLC • Oligometastatic disease and brain metastases
Author: Mary O'Brien Publisher: Karger Medical and Scientific Publishers ISBN: 3318070106 Category : Medical Languages : en Pages : 148
Book Description
Despite an overall decrease in tobacco use, lung cancer (80–85% of which is non-small-cell lung cancer [NSCLC]) is still the leading cause of cancer death in both men and women worldwide. Annual low-dose CT screening of high-risk individuals has the potential to detect early-stage tumors, which can usually be successfully treated with a combination of surgery, radiotherapy and chemotherapy and, in some cases, targeted therapy. However, most patients with NSCLC still present with advanced or metastatic disease. For these patients, initial therapy is guided by the tumor’s molecular characteristics and patient’s performance status. Targeted therapies have significantly improved clinical outcomes and, for some patients with no targetable genetic alterations, immunotherapy has demonstrated significant overall survival benefit. This insightful guide is designed to bring you up to speed with the latest developments and is important reading for all health professionals and medical trainees working in this fast-moving field. Table of Contents: • Prevention and screening • Diagnosis and staging • Surgery • Radiotherapy • Systemic therapy in non-metastatic NSCLC • Systemic therapy in advanced-stage/metastatic disease without a molecular driver • Personalized treatment in advanced NSCLC • Oligometastatic disease and brain metastases
Author: Anne-Marie Baird Publisher: Karger Medical and Scientific Publishers ISBN: 3318072494 Category : Medical Languages : en Pages : 39
Book Description
Non-small cell lung cancer (NSCLC) is one of two main types of lung cancer. Some lung cancers spread to other parts of the body before they are diagnosed. A cancer that has spread is called ‘metastatic’. New lung cancer treatments are being developed that directly target the gene mutations that control how cancers grow and spread. The most important gene mutations in cancer are called ‘driver mutations’. In NSCLC, this includes KRAS mutations, which can be used as targets for treatment. There are new treatments designed for lung cancers with a KRAS mutation that are already available. And more are being developed. Treatments in development are tested in clinical trials. There are several different phases of clinical trials that people with cancer can take part in. This booklet aims to help patients with NSCLC understand their options so that they can talk to their doctors, nurses, and medical team about their cancer and its treatment. Table of Contents: • What is non-small cell lung cancer? • How can lung cancer develop? • What is metastatic NSCLC? • More about genes and cancer • Oncogenes and cancer • Driver mutations and biomarkers • How your doctor knows your cancer is KRAS-positive • More about KRAS • What does having a KRAS-positive cancer mean for me? • Talking to your doctor about your treatment • About clinical trials and research • Finding further information and support
Author: Stephen Clarke Publisher: Karger Medical and Scientific Publishers ISBN: 3318068217 Category : Medical Languages : en Pages : 128
Book Description
The treatment of cancer has been revolutionized by therapies that modulate the immune system, with benefits for quality of life and survival. Standards of care have changed to reflect developments, but the area is moving fast. Keeping abreast of new therapies and trial data can be challenging. This second edition of 'Fast Facts: Immuno-Oncology' takes you from the fundamentals of immunology through to the new concepts of immunoediting and immunotherapy and likely future directions. Whether you have worked in oncology for decades and need a refresher or you are just starting out and need a crash course, this book provides all you need to know about immuno-oncology, concisely summarized. Table of Contents: • Components of the immune system • How cancers evade the immune system • How cancer immunotherapy works • Clinical use of immune checkpoint inhibitors • The future of immuno-oncology
Author: A.-M. Baird Publisher: Karger Medical and Scientific Publishers ISBN: 331807277X Category : Medical Languages : en Pages : 39
Book Description
Non-small cell lung cancer (NSCLC) is one of two main types of lung cancer. Some lung cancers spread to other parts of the body before they are diagnosed. A cancer that has spread is called ‘metastatic’. New lung cancer treatments are being developed that directly target the gene mutations that control how cancers grow and spread. The most important gene mutations in cancer are called ‘driver mutations’. In NSCLC, this includes KRAS mutations, which can be used as targets for treatment. There are new treatments designed for lung cancers with a KRAS mutation that are already available. And more are being developed. Treatments in development are tested in clinical trials. There are several different phases of clinical trials that people with cancer can take part in. This booklet aims to help patients with NSCLC understand their options so that they can talk to their doctors, nurses, and medical team about their cancer and its treatment. Table of Contents: • What is non-small cell lung cancer? • How can lung cancer develop? • What is metastatic NSCLC? • More about genes and cancer • Oncogenes and cancer • Driver mutations and biomarkers • How your doctor knows your cancer is KRAS-positive • More about KRAS • What does having a KRAS-positive cancer mean for me? • Talking to your doctor about your treatment • About clinical trials and research • Finding further information and support
Author: American Cancer Society Publisher: ISBN: 9780944235690 Category : Lungs Languages : en Pages : 228
Book Description
A comprehensive guide to lung cancer that covers the different types of lung cancer, risk factors and causes, prevention and detection, diagnosis and staging, treatments, and research on the disease. Includes resources.
Author: Kell Österlind Publisher: Health Press (UK) ISBN: 9781903734766 Category : Medical Languages : en Pages : 90
Book Description
More people die in the developed world from lung cancer than breast, prostate and colorectal cancer combined. Useful for primary healthcare physicians, this text provides information on the surgical and non surgical therapeutic strategies.
Author: Bernardo L. Rapoport Publisher: Karger Medical and Scientific Publishers ISBN: 3318068187 Category : Medical Languages : en Pages : 109
Book Description
Cancer is a multifaceted disease in which genetic changes induce uncontrolled tumor growth. Genomic characterization of cancer is now leading to better diagnostic, prognostic and predictive biomarkers, and effective individualized management. 'Fast Facts: Comprehensive Genomic Profiling' provides a crash course in the science, methods and application of genomic profiling. Assuming only the most basic knowledge – or memory – of cell biology, the authors provide an overview of DNA and RNA biology and next-generation sequencing. This sets in context the descriptions of prognostic and predictive biomarkers for different cancer types and genomic-based treatments. Finally, but importantly, some of the practicalities of gaining and interpreting genomic information are described. Whether you need a primer or a refresher, this short colorful book demystifies this complex subject. Contents: • Genetic mutations and biomarkers • Understanding next-generation sequencing • Elements of comprehensive genomic profiles • Role in precision oncology • Predictive and prognostic biomarkers • Overcoming barriers to genotype-directed therapy
Author: Roger S. Kirby Publisher: Karger Medical and Scientific Publishers ISBN: 1910797375 Category : Medical Languages : en Pages : 138
Book Description
Prostate cancer is unusual among solid tumors in that the majority of affected men die with, rather than of, the disease. This presents many challenges to healthcare professionals and patients in terms of deciding if, when and how to intervene in order to control tumor growth and spread, thereby extending survival but without compromising quality of life. This is the ninth edition of 'Fast Facts: Prostate Cancer' since 1996, testament to the rapid changes in the field and the steadily improving outlook for patients. This new edition provides many key updates: • the Gleason grade grouping, which has valuable prognostic value • nomograms to evaluate risk • our rapidly expanding understanding of the genetics and underlying pathogenesis of prostate cancer and the development of genomic tests to help identify those at greatest risk of developing clinically significant disease • the continuing debate about the role of PSA in the screening, detection and monitoring of prostate cancer • advances in imaging techniques, particularly multiparametric MRI, which is improving the accuracy of biopsy and reducing the numbers of negative biopsies • the roles of drugs, surgery and radiotherapy in the treatment of prostate cancer at different stages, and our ever-improving understanding of when and how best to intervene, aided by improving understanding of the risk factors for disease progression. Primarily intended for primary care providers, specialist nurses, junior doctors and allied healthcare professionals, this highly readable resource provides a comprehensive overview of prostate cancer, enabling fully informed discussions with patients about this complex disease. Contents: • Epidemiology and pathophysiology • Diet, lifestyle and chemoprevention • Screening and early detection • Diagnosis, staging and prognostic indicators • Management of clinically localized disease • Managing recurrence after initial therapy • Management of metastatic prostate cancer • Management of castrate-resistant prostate cancer • Survivorship and treatment complications
Author: Walter J. Scott Publisher: Addicus Books ISBN: 1936374382 Category : Health & Fitness Languages : en Pages : 127
Book Description
What is my prognosis? What are my treatment options? Which therapies would be the most effective for my stage of lung cancer? These and other frequently asked questions are addressed in this crucial reference designed to help patients educate themselves and obtain the best possible treatments. The completely revised second edition has been updated to include a discussion of the movement towards customized chemotherapy; treatment options for early-stage lung cancer including minimally invasive surgery; and the most promising treatments, among them multimodality therapy—a combination of surgery, chemotherapy, and radiation. Dr. Scott also surveys tests for early detection of lung cancer, talks about the importance of cancer staging, examines alternative treatments, and offers advice on coping with emotions such as "smoker's guilt."
Author: Paul Cornes Publisher: Karger Medical and Scientific Publishers ISBN: 1912776219 Category : Medical Languages : en Pages : 130
Book Description
Biologics have revolutionized – and are revolutionizing – the treatment of many serious disorders. The evidence acquired from more than 10 years of clinical experience, with more than 50 biosimilar drugs and more than 700 million patient-days' exposure in Europe, shows that approved biosimilars can be used as safely and effectively as originator biologics. Yet concerns persist about biosimilars – particularly in curative cancer treatment, where they are relatively recent therapeutic options. 'Fast Facts: Biosimilars in Hematology and Oncology' provides a concise overview of emerging global practice in this fast-moving area together with practical information on adding biosimilars to a formulary and switching patients. Contents: • Biologics and the need for biosimilars • Why do we need biosimilars? • How is the quality of biosimilar medicines assured? • Legal issues • Switching, interchangeability and extrapolation • Safety and pharmacovigilant • Global issues • Formulary considerations: pharmacy issues • Formulary considerations: supportive care biosimilars • Formulary considerations: therapeutic anti-cancer biosimilars • Communication and awareness
Author: Mary O'Brien
Author: Mary O'Brien
Author: Anne-Marie Baird
Author: Stephen Clarke
Author: A.-M. Baird
Author: American Cancer Society
Author: Kell Österlind
Author: Bernardo L. Rapoport 
Author: Roger S. Kirby
Author: Walter J. Scott
Author: Paul Cornes